Correction to: NALIRIFOX Compared With FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma: An Overall Survival External Control Arm Study
King DA, Duh MS, Chang R, et al. NALIRIFOX Compared With FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma: An Overall Survival External Control Arm Study. J Clin Pathways. 2026;12(2):e002. doi:10.25270/jcp.2026.03.002 was published before the authors had the opportunity to review page proofs. After publication, the authors reviewed the published article and identified corrections needed to clarify terminology, cohort descriptions, wording, formatting, references, disclosures, and figure/table presentation. The article has been updated, and a detailed change log is published with this corrigendum. The authors confirm that these corrections do not affect the study results, interpretation, or conclusions and that they stand by the work.
View the table of changes here.
View the updated article here.
View the original version here.
Authors: Daniel A. King (MD, PhD)1; Mei Sheng Duh (ScD)2; Rose Chang (ScD)2; Louise Yu (MS)2; Chunyi Xu (MS)2; Eric M. Maiese (PhD)3*; George Kim (MD)4
Affiliations: 1Northwell Health, New Hyde Park, NY; 2Analysis Group, Inc, Boston, MA; 3Ipsen Biopharmaceuticals, Inc, Cambridge, MA; 4Division of Hematology and Oncology, University of Florida, Gainesville, FL
Correspondence: Daniel A. King, MD, PhD; dking14@northwell.edu
